Clinical trial NCT05376618: Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology
Official title: Pilot Study on Proteomics of Erythrocyte Proteins in Patients With Chronic Obstructive Pulmonary Disease Based on TMT Technology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Protein; Disease
Keywords: copd
erythrocyte
proteomics
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2022-05-17
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study will be an outpatient-based case-control study. 15 stable COPD patients and 15 healthy individuals will be recruited.

Brief summary: Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition. Further investigations on the cellular and molecular aspects of hypoxia in COPD should help to reveal the mechanisms underlying the development of this disease. Dysfunction of the erythrocyte, a main medium to transport oxygen through the blood, contributes to the prognosis and severity of COPD through hypoxia. It is proposed that dysregulated proteins in erythrocytes that impair oxygen transport may be involved in the development of COPD. However, a comprehensive study on altered proteins of erythrocytes in COPD is still lacking. Proteomics techniques and protein chip techniques provide a high throughput screening method to figure out characteristic inflammatory or metabolic markers of diseases. Therefore, this study is to evaluate the clinical significance of differential erythrocyte proteins in the course of COPD disease.


Eligibility criteria: 1. case group

   Inclusion Criteria:
   1. Age from 40 to 80 years old; gender is not limited.
   2. Stable COPD
   3. Sign the informed consent with the willingness of obeying the protocol. -

   Exclusion Criteria:
   1. Subjects with known other chronic respiratory diseases except for COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
   2. Subjects had been accepted lung lobectomy or transplantation;
   3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
   4. Alcoholism, drug or solvents addition;
   5. Acute exacerbation COPD patients (AECOPD) -
2. control group Inclusion criteria

   1. Age from 40 to 80 years old; gender is not limited.
   2. Sign the informed consent with the willingness of obeying the protocol. - Exclusion criteria

   <!-- -->

   1. Subjects with known other chronic respiratory diseases (such as COPD, asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
   2. Subjects had been accepted lung lobectomy or transplantation;
   3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
   4. Alcoholism, drug or solvents addition;

Primary outcomes:
measure: Protein biomarkers in erythrocyte predicting rapid decline of lung function
timeFrame: 2021-7-15 to 2022-7-15
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang Hospital,Southern Medical Universtiy
state: Guangdong
Study officials:
References: